DK0419251T3 - Proteinholdige vandige opløsninger - Google Patents

Proteinholdige vandige opløsninger

Info

Publication number
DK0419251T3
DK0419251T3 DK90310287.9T DK90310287T DK0419251T3 DK 0419251 T3 DK0419251 T3 DK 0419251T3 DK 90310287 T DK90310287 T DK 90310287T DK 0419251 T3 DK0419251 T3 DK 0419251T3
Authority
DK
Denmark
Prior art keywords
protein
proteinous
aqueous solutions
aqueous
dissolved
Prior art date
Application number
DK90310287.9T
Other languages
English (en)
Inventor
Yukio Shimazaki
Nobuhiro Kawashima
Miki Yoshioka
Yasuhito Tanaka
Ryo Tanaka
Kiyoshi Sakai
Hisahiro Ishiwari
Original Assignee
Mitsui Toatsu Chemicals
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals, Mochida Pharm Co Ltd filed Critical Mitsui Toatsu Chemicals
Application granted granted Critical
Publication of DK0419251T3 publication Critical patent/DK0419251T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90310287.9T 1989-09-21 1990-09-20 Proteinholdige vandige opløsninger DK0419251T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1243311A JPH0791318B2 (ja) 1989-09-21 1989-09-21 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤

Publications (1)

Publication Number Publication Date
DK0419251T3 true DK0419251T3 (da) 1994-01-31

Family

ID=17101947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90310287.9T DK0419251T3 (da) 1989-09-21 1990-09-20 Proteinholdige vandige opløsninger

Country Status (14)

Country Link
EP (1) EP0419251B1 (da)
JP (1) JPH0791318B2 (da)
KR (1) KR930004598B1 (da)
CN (1) CN1049356C (da)
AT (1) ATE93731T1 (da)
AU (1) AU627621B2 (da)
BR (1) BR9004693A (da)
CA (1) CA2025315C (da)
DE (1) DE69003061T2 (da)
DK (1) DK0419251T3 (da)
ES (1) ES2060057T3 (da)
FI (1) FI98891C (da)
NO (1) NO904120L (da)
NZ (1) NZ235297A (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635051T2 (de) * 1995-06-07 2006-06-14 Chiron Corp Methode zur lösung, reinigung und rückfaltung von protein
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107185A (en) * 1981-10-07 1983-04-27 John Kenneth Mcmullen Insulin formulations containing surface-active agents
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
DE3512908A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel
JPS61289886A (ja) * 1985-06-19 1986-12-19 Agency Of Ind Science & Technol 酵素及び／又は微生物含有アルギン酸繊維紙の製造法
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
JPH02111726A (ja) * 1988-10-19 1990-04-24 Dainippon Pharmaceut Co Ltd ヒト　インターロイキン１を安定化する方法

Also Published As

Publication number Publication date
KR930004598B1 (ko) 1993-06-01
DE69003061D1 (de) 1993-10-07
ATE93731T1 (de) 1993-09-15
EP0419251A1 (en) 1991-03-27
CN1049356C (zh) 2000-02-16
FI904618A0 (fi) 1990-09-19
NO904120L (no) 1991-03-22
EP0419251B1 (en) 1993-09-01
FI98891B (fi) 1997-05-30
JPH03106898A (ja) 1991-05-07
AU6246690A (en) 1991-03-28
AU627621B2 (en) 1992-08-27
DE69003061T2 (de) 1993-12-16
KR910005884A (ko) 1991-04-27
JPH0791318B2 (ja) 1995-10-04
CA2025315C (en) 1997-01-07
CN1050327A (zh) 1991-04-03
ES2060057T3 (es) 1994-11-16
FI98891C (fi) 1997-09-10
BR9004693A (pt) 1991-09-10
NO904120D0 (no) 1990-09-20
CA2025315A1 (en) 1991-03-22
NZ235297A (en) 1992-12-23

Similar Documents

Publication Publication Date Title
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
FI914241A0 (fi) Vacciner foer icke-typade haemo philus influenzae-bakterier.
FI870169A0 (fi) Stabiliserat tokoferol i fri-flytande partikelform.
DK179286D0 (da) Insulinpraeparat
ATE66140T1 (de) Salbengrundlage und salbe.
ATE114319T1 (de) Produktion von proteinen in aktiven formen.
SE8602405D0 (sv) Ny formulering
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
SE7904118L (sv) Sett att framstella en urokinaskomposition
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
ES2043609T3 (es) Composiciones de interleucina-2.
FI882605A0 (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
DE60043994D1 (de) Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung
DK0419251T3 (da) Proteinholdige vandige opløsninger
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
DK0431465T3 (da) Vandig dialyse- og skylleopløsning
DK164916C (da) Fremgangsmaade til rensning eller berigelse af biologisk aktive proteiner og hertil egnet middel
DK0686694T3 (da) Anvendelse af azoler som virucide midler i opløsninger af biologisk aktive proteiner
FR2597750B1 (fr) Solution aqueuse stable de sulfate de vincristine
BG31214A3 (en) Method for obtaining of human albumine
ATE78402T1 (de) Waesserige loesungen von doxorubicin.
ATE80306T1 (de) Mittel zur absorptionsverbesserung von proteinen.
NO862740D0 (no) Fremgangsmaate for stabilisering av xantangummi i vandig loesning.